We are live on ! Find out more
KNTE

Kinnate Biopharma Inc. Common Stock
KNTE

Delisted

KNTE was delisted on the 2nd of April, 2024.

Back to rankings

55 hedge funds and large institutions have $1.43B invested in Kinnate Biopharma Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 55 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
55
Holders Change
+55
Holders Change %
–
% of All Funds
0.97%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.11%
New
55
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management IV
California
+$388M
2
O
OrbiMed
New York
+$154M
3
RCM
RA Capital Management
Massachusetts
+$144M
4
VVA
Vida Ventures Advisors
Massachusetts
+$110M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$98.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
FCMI
1
Foresite Capital Management IV
California
$385M +$388M +9,671,643 New
O
2
OrbiMed
New York
$153M +$154M +3,847,929 New
RCM
3
RA Capital Management
Massachusetts
$143M +$144M +3,593,052 New
VVA
4
Vida Ventures Advisors
Massachusetts
$109M +$110M +2,747,074 New
Fidelity Investments
5
Fidelity Investments
Massachusetts
$94.1M +$98.3M +2,450,135 New
Viking Global Investors
6
Viking Global Investors
Connecticut
$74.5M +$75.1M +1,872,023 New
VA
7
VR Adviser
New York
$58.6M +$59.1M +1,473,014 New
Citadel Advisors
8
Citadel Advisors
Florida
$52.3M +$52.8M +1,315,500 New
BC
9
Boxer Capital
California
$42.4M +$42.7M +1,064,665 New
FCMV
10
Foresite Capital Management V
California
$34.8M +$35.1M +875,001 New
Vanguard Group
11
Vanguard Group
Pennsylvania
$33.9M +$34.2M +851,838 New
Janus Henderson Group
12
Janus Henderson Group
United Kingdom
$30.4M +$32.3M +805,769 New
T. Rowe Price Associates
13
T. Rowe Price Associates
Maryland
$25.8M +$26.1M +649,406 New
LGM
14
Logos Global Management
California
$22.7M +$22.9M +569,602 New
HMC
15
Harvard Management Company
Massachusetts
$19.8M +$20M +498,001 New
DM
16
Deerfield Management
New York
$13.7M +$13.8M +345,000 New
PHS
17
PFM Health Sciences
California
$13.6M +$13.7M +341,905 New
RSCM
18
Rock Springs Capital Management
Maryland
$12.9M +$13M +324,686 New
BlackRock
19
BlackRock
New York
$12.3M +$12.4M +309,544 New
NHAS
20
Novo Holdings A/S
Denmark
$11.9M +$12M +300,000 New
WP
21
Woodline Partners
California
$11M +$11.1M +276,451 New
FCM
22
Farallon Capital Management
California
$9.95M +$10M +250,000 New
Federated Hermes
23
Federated Hermes
Pennsylvania
$9.95M +$10M +250,000 New
EAM
24
Eventide Asset Management
Massachusetts
$6.96M +$7.02M +175,000 New
Franklin Resources
25
Franklin Resources
California
$6.96M +$7.02M +175,007 New
1
2 3

KNTE Hedge Fund Activity: Q4 2020 in Review

55 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Kinnate Biopharma Inc. Common Stock (KNTE) for Q4 2020, worth a combined $1.43B.

Buyers outnumbered sellers: 55 funds opened new KNTE positions and 0 closed out — a net gain of 55 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $388M.

  • 55 institutional investors held Kinnate Biopharma Inc. Common Stock (KNTE) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $1.43B of Kinnate Biopharma Inc. Common Stock stock for Q4 2020.
  • 55 funds opened new Kinnate Biopharma Inc. Common Stock positions in Q4 2020 and 0 closed out, a net change of +55 holders.
  • The largest Kinnate Biopharma Inc. Common Stock buyer in Q4 2020 was Foresite Capital Management IV, an estimated $388M added.

Based on aggregated 13F filings for Q4 2020.